Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 01, 2025 08:00 ET | Source: Cancer Focus Fund; ImmunoGenesis

ImmunoGenesis Expands Phase 1a/b Trial of IMGS-001 for Advanced Solid Tumors to Ochsner MD Anderson Cancer Center

The Phase 1 trial of IMGS-001-a novel dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function-is expanding to Ochsner MD Anderson Cancer Center.
October 23, 2024 07:00 ET | Source: Cancer Focus Fund; Starget Pharma

Starget Pharma and Cancer Focus Fund Announce $5.1 Million Investment to Support Phase 1b Clinical Trial of Novel Peptide Radioligand for Precision Cancer Therapy

Cancer Focus Fund invested $5.1M in precision peptide radioligand developer Starget for a Phase 1b trial at MD Anderson of its lead theranostic DOTA-PTR-58
March 21, 2024 07:00 ET | Source: Cancer Focus Fund; Eisbach Bio GmbH

Eisbach and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Phase 1/2 Trial of EIS-12656 for Refractory Advanced Solid Tumors

Cancer Focus Fund is investing $4.5M for clinical trial of Eisbach's novel approach using synthetic lethality to kill PARP inhibitor resistant tumors